The Polish Ministry of Health has approved Tilray-branded medical cannabis for pharmaceutical distribution.
Tilray Medical has bolstered its position in Europe with market authorisation in Poland. The Canadian company has received approval to commercialise its medical cannabis products in the country, expanding its product offering and distribution across pharmacies in Europe.
Denise Faltischek, Tilray’s chief strategy officer and head of international business, said: “I’m extremely proud of our team in Europe for once again expanding our approved authorisation for Tilray Medical products across Europe. Tilray will continue to advocate for reasonable patient access to reliable and high-quality medical cannabis in Europe and countries around the world.”
In Poland, the company has established multiple partnerships with pharmaceutical companies to distribute both branded and unbranded medical cannabis products. Patients can obtain prescriptions for medical cannabis in Poland through their preferred medical doctor.
Tilray Medical is a leading international provider of EU-GMP-certified medical cannabis products with a portfolio of THC and CBD-based medicines. The company said its products have been “selected to ensure patients can receive both the highest product quality and consistency when it comes to supply of their medicinal cannabis products.”
The company has a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast and Symbios. The company grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first EU-GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany.
Today, it is one of the biggest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers and governments, in 21 countries and across five continents.
Last month, Tilray Medical’s parent company Tilray Brands reported record results for the 2022 fiscal year with net revenue of $628 million, a 22 per cent increase compared to the prior year.
Estimated reading time: 2 minutes
